Hikma Pharmaceuticals Plc Total Voting Rights (1121E)
May 03 2017 - 12:23PM
UK Regulatory
TIDMHIK
RNS Number : 1121E
Hikma Pharmaceuticals Plc
03 May 2017
Hikma Pharmaceuticals PLC
Total Voting Rights and Capital
LONDON, 3 May 2017, Hikma Pharmaceuticals PLC (LEI:
549300BNS685UXH4JI75) (LSE: HIK) (NasdaqDubai: HIK) notifies the
market that its capital consists of 240,266,361 ordinary shares
with voting rights. There are nil shares held in treasury.
The above figure may be used by shareholders as the denominator
for the calculations by which they will determine if they are
required to notify their interest in, or a change to their interest
in, Hikma Pharmaceuticals PLC under the FCA's Disclosure and
Transparency Rules.
- ENDS -
Enquiries
Hikma Pharmaceuticals PLC
Peter Speirs
Company Secretary +44 20 7399 2760
About Hikma
Hikma Pharmaceuticals PLC is a fast growing pharmaceutical group
focused on developing, manufacturing and marketing a broad range of
both branded and non-branded generic and in-licensed products.
Hikma's operations are conducted through three businesses:
"Branded", "Injectables" and "Generics" based primarily in the
Middle East and North Africa ("MENA") region, where it is a market
leader, the United States and Europe. In 2016, Hikma achieved
revenues of $1,950 million and profit attributable to shareholders
of $155 million.
This information is provided by RNS
The company news service from the London Stock Exchange
END
TVREAKSDEADXEFF
(END) Dow Jones Newswires
May 03, 2017 12:23 ET (16:23 GMT)
Hikma Pharmaceuticals (LSE:HIK)
Historical Stock Chart
From Jun 2024 to Jul 2024
Hikma Pharmaceuticals (LSE:HIK)
Historical Stock Chart
From Jul 2023 to Jul 2024